Niagen Bioscience to Present at the 38th Annual ROTH Conference

About this update from Niagen Bioscience, Inc.

LOS ANGELES --(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the 38th Annual ROTH Conference , taking place at The Ritz-Carlton Laguna Niguel in Dana Point, California , from March 22 to 24, 2026 . Niagen Bioscience CEO, Rob Fried , will participate in the Technologies Advancing Healthy Aging Panel on Monday, March 23 , at 2:00 PM PT ( 5:00 PM ET ). The panel will be livestreamed and available at www.event.summitcast.com . Additionally, Niagen Bioscience’s CEO, Rob Fried , and CFO, Ozan Pamir , will attend one-on-one meetings with institutional investors in person throughout the day. This year’s event will consist of one-on-one and small-group meetings, analyst-selected fireside chats, industry keynotes, and panels, with executive management from hundreds of private and public companies across a variety of growth sectors in attendance. Investors interested in arranging one-on-one meetings should contact their ROTH representative. To learn more and submit a registration request, click here . The Technologies Advancing Healthy Aging Panel will be livestreamed and available at www.event.summitcast.com . For additional information on Niagen Bioscience , visit www.niagenbioscience.com . About Niagen Bioscience : Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience ™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age. At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com ), and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( www.niagenplus.com ). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com , where copies of press releases, news, and financial information are regularly published. †Based on revenue per largest U.S. e-commerce marketplace ( Jan. 2025 – Dec. 2025 ) About ROTH: ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Their full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California , ROTH is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information, please visit www.roth.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20260318201122/en/ Niagen Bioscience Media Contact: Kendall Knysch , Senior Director of Media Relations & Partnerships 310.405.5227 [email protected] Niagen Bioscience Investor Relations Contact: Valter Pinto , Managing Director KCSA Strategic Communications 212.896.1254 [email protected] Source: Niagen Bioscience, Inc

View stock analysis, news, and events for Niagen Bioscience, Inc.